Mangrove Partners IM LLC Buys New Holdings in Molina Healthcare, Inc $MOH

Mangrove Partners IM LLC bought a new position in Molina Healthcare, Inc (NYSE:MOH) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,252 shares of the company’s stock, valued at approximately $814,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of MOH. CYBER HORNET ETFs LLC acquired a new position in shares of Molina Healthcare in the 2nd quarter valued at $45,000. MUFG Securities EMEA plc acquired a new stake in shares of Molina Healthcare during the 2nd quarter valued at about $48,000. Bogart Wealth LLC acquired a new stake in shares of Molina Healthcare during the 3rd quarter valued at about $39,000. SJS Investment Consulting Inc. increased its stake in Molina Healthcare by 6,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 253 shares of the company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Molina Healthcare in the third quarter valued at about $50,000. Institutional investors own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. The Goldman Sachs Group cut their price target on shares of Molina Healthcare from $167.00 to $124.00 and set a “neutral” rating for the company in a research note on Wednesday, February 11th. Barclays lowered their price objective on Molina Healthcare from $164.00 to $133.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 10th. Morgan Stanley dropped their target price on Molina Healthcare from $158.00 to $128.00 and set an “equal weight” rating for the company in a report on Wednesday, March 4th. Cantor Fitzgerald cut their target price on Molina Healthcare from $180.00 to $144.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, UBS Group set a $173.00 price target on Molina Healthcare in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $169.21.

Molina Healthcare Stock Performance

Shares of Molina Healthcare stock opened at $149.08 on Friday. The firm has a market cap of $7.68 billion, a P/E ratio of 17.42 and a beta of 0.52. The company has a debt-to-equity ratio of 0.97, a current ratio of 1.69 and a quick ratio of 1.69. The firm has a 50 day simple moving average of $163.64 and a 200 day simple moving average of $167.17. Molina Healthcare, Inc has a fifty-two week low of $121.06 and a fifty-two week high of $359.97.

Molina Healthcare (NYSE:MOH) last released its earnings results on Thursday, February 5th. The company reported ($2.75) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($3.18). Molina Healthcare had a return on equity of 13.60% and a net margin of 1.04%.The firm had revenue of $11.38 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the firm earned $5.05 EPS. The company’s revenue was up 8.3% compared to the same quarter last year. Molina Healthcare has set its FY 2026 guidance at 5.000- EPS. Sell-side analysts predict that Molina Healthcare, Inc will post 24.4 earnings per share for the current fiscal year.

Molina Healthcare Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.